Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Chronic Kidney Disease
NCT03036150Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of dapagliflozin in chronic kidney disease (CKD), sponsored by AstraZeneca. Started Feb 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03036150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036150.